This is a list of investigational antipsychotics, or drugs that are currently under development for clinical use as antipsychotics for the treatment of schizophrenia and other psychotic disorders but are not yet approved. Psychotic disorders include schizophrenia, schizoaffective disorder, and others such as psychotic depression, Parkinson's disease psychosis, and Alzheimer's disease psychosis.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".
This list was last comprehensively updated in June 2026. It is likely to become outdated with time.
Under development Preregistration Olanzapine long acting injectable (mdc-TJK; TEV-749; TV-44749) – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Roluperidone (CYR-101; MIN-101; MT-210) – serotonin 5-HT2A receptor antagonist, sigma σ2 receptor antagonist, and other actions – schizophrenia
Phase 3 Brilaroxazine (RP-5000; RP-5063; oxaripiprazole) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Direclidine (HTL-0016878; NBI-1117568; NBI-568) – muscarinic acetylcholine M4 receptor agonist – schizophrenia Evenamide (EA-8001; NW-3509; NW-3509A) – voltage-gated sodium channel (VGSC) blocker – schizophrenia Iclepertin (BI-425809) – glycine transporter 1 (GlyT1) inhibitor – schizophrenia N-Methylamisulpride (LB-102) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT2B receptor antagonist, and serotonin 5-HT7 receptor antagonist – schizophrenia Remlifanserin (ACP-204) – serotonin 5-HT2A receptor inverse agonist – psychotic disorders Risperidone extended release (LYN-005) – dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist – schizophrenia, schizoaffective disorder Ulotaront (SEP-363856; SEP-856) – trace amine-associated receptor 1 (TAAR1) agonist and serotonin 5-HT1A receptor agonist – schizophrenia Valbenazine (Dysval; Ingrezza; MT-5199; NBI-98854; Remleas) – vesicular monoamine transporter 2 (VMAT2) blocker and monoamine depleting agent – schizophrenia Xanomeline enteric coated (BMS-986519; KarX-EC; LY-246708; Memcor; NNC-110232) – muscarinic acetylcholine M1 and M4 receptor agonist – psychotic disorders Xanomeline/trospium chloride (BMS-986510; Cobenfy; KarXT; trospium/LY-246708; trospium/xanomeline) – combination of xanomeline (muscarinic acetylcholine M1 and M4 receptor agonist) and trospium chloride (peripherally selective non-selective muscarinic acetylcholine receptor antagonist) – psychotic disorders
Phase 2/3 AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist – schizophrenia Deudextromethorphan (AVP-786; CTP-786; d-DM; d6-DM; deudextromethorphan/quinidine; deuterated dextromethorphan; deuterated-DM) – combination of deudextromethorphan (sigma receptor agonist, ionotropic glutamate NMDA receptor antagonist, serotonin reuptake inhibitor, other actions) and quinidine (CYP2D6 inhibitor) – schizophrenia Sodium benzoate (benzoate; Clozaben; NaBen; SND-51; SND-11; SND-12; SND-13; SND-14; Tannquilynne; Ω-NaBen) – D-amino acid oxidase inhibitor – schizophrenia
Phase 2 Alofropodect (CPL-500036; CPL'36; CPL-500-036-02; CPL500036; CZ20; PG203; SUB193569) – phosphodiesterase PDE10A inhibitor – schizophrenia ANAVEX 3-71 (ANAVEX3-71; AF710B; AF-710B) – muscarinic acetylcholine M1 receptor positive allosteric modulator and sigma σ1 receptor agonist – schizophrenia Balipodect (AXS-20; TAK-063) – phosphodiesterase PDE10A inhibitor – schizophrenia Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist and gastric inhibitory polypeptide (GIP) receptor agonist – schizophrenia Brilaroxazine (RP-5000; RP-5063; oxaripiprazole) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizoaffective disorder Emraclidine (CVL-231; PF-06852231) – muscarinic acetylcholine M4 receptor positive allosteric modulator – schizophrenia FKF-02SC (FKF02SC; TGOF-02N) – dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist – schizophrenia GXV-813 (EX-A8078) – muscarinic acetylcholine M4 receptor agonist – schizophrenia HS-10380 – undefined mechanism of action – schizophrenia Idazoxan extended release (TR-01-IR; TR-01-XR; TR-01-XRR; TR-01-XRS) – α2-adrenergic receptor antagonist – schizophrenia Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – psychotic disorders KYN-5356 (MT-5356) – kynurenine aminotransferase 2 (KAT-II) inhibitor – schizophrenia Lu AF11167 (Lu-AF-11167) – phosphodiesterase PDE10A inhibitor – schizophrenia Lumateperone deuterated (ITI-1284; ITI-1284 ODT-SL) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – psychotic disorders Luvadaxistat (NBI-1065844; TAK-831) – D-amino acid oxidase inhibitor – schizophrenia LY-03017 (LPM-526000133; LPM526000133) – serotonin 5-HT2A and 5-HT2C receptor antagonist – schizophrenia LY-03020 (LPM-787000048; LPM787000048) – trace amine-associated receptor 1 (TAAR1) agonist and serotonin 5-HT2C receptor agonist – schizophrenia Masupirdine (M1; M1 of SUVN-502; SUVN502; SVN-502) – serotonin 5-HT6 receptor antagonist – schizophrenia ML-007/muscarinic antagonist (ML-007/PAC; ML-007C-MA) – combination of ML-007 (muscarinic acetylcholine M1 and M4 receptor agonist) and a muscarinic acetylcholine receptor antagonist – schizophrenia, psychotic disorders Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate NMDA receptor glycine site positive allosteric modulator – schizophrenia NS-136 – muscarinic acetylcholine M4 receptor positive allosteric modulator – schizophrenia Osoresnontrine (BI-409306; SUB-166499) – phosphodiesterase PDE9A inhibitor – schizophrenia, psychotic disorders Pomaglumetad methionil (DB103; DB-103; LY-2140023; LY2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (pomaglumetad prodrug) – schizophrenia Pyridoxamine (BST-4001; K-163; K163SZ; Pyridorin) – vitamin B6 and antioxidant – schizophrenia Sodium benzoate (benzoate; Clozaben; NaBen; SND-51; SND-11; SND-12; SND-13; SND-14; Tannquilynne; Ω-NaBen) – D-amino acid oxidase inhibitor – psychotic disorders Tazbentetol (SPG302; SPG-302) – undefined mechanism of action (targets an undisclosed regulator of the F-actin-based cytoskeleton to increase synaptogenesis) – schizophrenia Vafidemstat (ORY-2001) – lysine-specific demethylase 1 (LSD-1) inhibitor and monoamine oxidase B (MAO-B) inhibitor – schizophrenia
Phase 1/2 Cariprazine depot – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Forvisirvat (SP-624) – sirtuin-6 (SIRT6) activator – schizophrenia PF-6412562 (PF6412562; PF-06412562; PF06412562) – dopamine D1 and D5 receptor partial agonist – schizophrenia SKL-15508 (SKL–A4R; SKL15508) – α7 nicotinic acetylcholine receptor agonist – schizophrenia
Phase 1 DSP-0038 – serotonin 5-HT1A receptor agonist and serotonin 5-HT2A receptor antagonist – psychotic disorders HTL-0048149 (HTL'149; HTL-0048149; HTL-A; NXE-0048149; NXE-149) – GPR52 agonist – schizophrenia LTX-001 – glutaminase inhibitor – schizophrenia MK-5720 – undefined mechanism of action – schizophrenia ML-007 – muscarinic acetylcholine M1 and M4 receptor agonist – psychotic disorders NMRA-861 – muscarinic acetylcholine M4 receptor positive allosteric modulator – schizophrenia NMRA-898 – muscarinic acetylcholine M4 receptor positive allosteric modulator – schizophrenia OV-4071 – K+Cl– cotransporter 2 (KCC2) direct activator – psychotic disorders SEP-380135 – undefined mechanism of action – schizophrenia Squalamine (ENT-01; Enterin-01; kenterin) – various actions – psychotic disorders VV-119 (VV119) – undefined mechanism of action (dopamine and serotonin receptor modulator) – schizophrenia Zelquistinel (AGN-241751; GATE-251) – ionotropic glutamate NMDA receptor positive allosteric modulator – schizophrenia
Clinical phase unknown Quetiapine oral suspension – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia
Preclinical BrAD-R13 (R13; Braegen-01) – tropomyosin receptor kinase B (TrkB) agonist (tropoflavin (7,8-dihydroxyflavone; 7,8-DHF) prodrug) – schizophrenia DPX-101 – α5 subunit-containing GABAA receptor positive allosteric modulator – schizophrenia EM-221 – phosphodiesterase PDE10A inhibitor – schizophrenia NMRA-861 – muscarinic acetylcholine M4 receptor positive allosteric modulator – psychotic disorders OV-4071 – K+Cl– cotransporter 2 (KCC2) direct activator – schizphrenia TPT-0901 – cannabinoid CB1 and CB2 receptor agonist – schizophrenia Xanomeline/trospium prodrug (TerXT) – prodrug of xanomeline (muscarinic acetylcholine M1 and M4 receptor agonist) and trospium chloride (peripherally selective non-selective muscarinic acetylcholine receptor antagonist) – schizophrenia
Phase unknown Quetiapine long acting injection (CP-103) – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – psychotic disorders
Not under development No development reported ADE-616 – undefined mechanism of action – schizophrenia AGX-201 (histamine dihydrochloride) – non-selective histamine receptor agonist – schizophrenia AMG-579 – phosphodiesterase PDE10A inhibitor – schizophrenia, schizoaffective disorder AMG-581 – undefined mechanism of action – schizophrenia, schizoaffective disorder Aripiprazole controlled release (ZY-102) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Aripiprazole oral soluble film – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Aripiprazole transdermal (AQS-1301) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia ASP-4345 (ASP4345) – dopamine D1 receptor positive allosteric modulator – schizophrenia BIMG-80 – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Brexpiprazole long-acting injectable (MTD-211) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Buspirone controlled release (buspirone ER) – serotonin 5-HT1A receptor agonist – schizophrenia Cannabidiol (CBD; Arvisol) – atypical cannabinoid and various actions – schizophrenia Cariprazine (CarMP-214; Reagila; RGH-188; Symvenu; Vraylar WID-RGC20) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia Clozapine modified-release – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia CM-182 – undefined mechanism of action – schizophrenia CVL-047 – phosphodiesterase PDE4 inhibitor – schizophrenia CY-150112 – undefined mechanism of action – schizophrenia GSK-729327 (GSK729327) – ionotropic glutamate AMPA receptor positive allosteric modulator – schizophrenia GT-001 (GT001) – GABAA receptor positive allosteric modulator – psychotic disorders HW-165 – dopamine D2 and D3 receptor partial agonist – schizophrenia JNJ-17305600 – glycine transporter 1 (GlyT1) inhibitor – schizophrenia JNJ-37822681 – dopamine D2 receptor antagonist – schizophrenia LM-007 – undefined mechanism of action – schizophrenia